Formulation and Evaluation of Quercetin Loaded Sago Starch Nanoparticles

Abstract

Aim: Formulation and evaluation of the QLSS nanoparticles as a drug delivery system. Background: Poor drug solubility and permeability, particularly in BCS Class IV drugs, hamper their pharmacokinetics and targeted action. This study aims to address this by utilizing starch nanoparticles as a novel carrier for enhanced delivery and improved bioavailability. Objective: Formulation of the QLSS nanoparticles and their % drug entrapment, drug loading, average particle size, surface morphological examination, in-vitro drug release study, and cytotoxicity activity using an MTT assay against the A549 cancer cell line. Method: QLSS nanoparticles were prepared by the nanoprecipitation technique with some modifications, &assessment, including surface morphological analysis, drug loading, drug entrapment percentage, average particle size, in-vitro drug release study, and cytotoxicity activity. result: The average particle size and surface morphology of prepared optimized QLSS nanoparticles (QLSS 3) were found to be approximately 43.24–113.51 nm and spherical in shape with a 292.1nm of Z-average size. The percentage yield was found to be 80% of QLSS-3. The percentages of drug encapsulation efficiency and loading capacity were found to be 68% and 42.5%, respectively. The drug in-vitro release outcomes were found to be 96.12±1.8% within 12 hours. 10µg/ml of QLSS 3 inhibited 66.31% of A549 cancer cells. Result: The average particle size and surface morphology of prepared optimized QLSS nanoparticles (QLSS 3) were found to be approximately 43.24-113.51 nm and spherical in shape with a 292.1nm Z-average size. The percentage yield was found to be 80 ± 2.0% of QLSS-3. Loading capacity and the percentages of drug encapsulation efficiency were found to be 42.5 ± 1.2% and 68 ± 2.2%, respectively. The results of the in-vitro drug's release were found to be 96.12 ± 1.8% within 12 hours. 10μg/ml of QLSS 3 inhibited 66.31 ± 1.4% of A549 cancer cells. Conclusion: In this research study, sago starch was used for the first time as a drug carrier for quercetin. The results of the studies confirmed the improvement in pharmacokinetic parameters of the BCS-IV class drug.